Arrowhead Pharmaceuticals Inc (STU:HDP1) Stock News, Headlines & Updates
Arrowhead Pharmaceuticals Inc Stock News from GuruFocus
- 1
Jun 23, 2025
Arrowhead (ARWR) Advances Phase 3 Trials for Plozasiran | ARWR Stock News
GuruFocus News • 12:18pm
Arrowhead Pharmaceuticals Completes Enrollment in Key Phase 3 Studies for Plozasiran | ARWR stock news
GuruFocus News • 7:06am
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
Business Wire • 7:00am
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran | ARWR Stock News
GuruFocus News • 6:47am
Jun 02, 2025
Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial for Obesity Treatment ARO-ALK7 | ARWR stock news
GuruFocus News • 8:21am
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News
GuruFocus News • 7:03am
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Business Wire • 7:00am
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News
GuruFocus News • 6:47am
May 29, 2025
Arrowhead Pharmaceuticals Inc (ARWR) Announces Participation in Upcoming Investor Conferences | ARWR stock news
GuruFocus News • 8:02am
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
Business Wire • 7:00am
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences | ARWR Stock News
GuruFocus News • 6:48am
May 20, 2025
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News
GuruFocus News • 7:00am
May 14, 2025
UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News
GuruFocus News • 8:30am
May 13, 2025
Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News
GuruFocus News • 2:32pm
Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Target | ARWR Stock News
GuruFocus News • 7:30am
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News
GuruFocus News • 5:58am
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and Strategic Advances Amid Market Challenges
GuruFocus News • 1:07am
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight
GuruFocus News • 11:03pm
Q2 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript
GuruFocus News • 11:02pm
Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch
GuruFocus News • 9:55pm
May 12, 2025
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
Business Wire • 4:00pm
Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News
GuruFocus News • 3:53pm
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2.75 and Revenue of $542.7 Million Surpass Estimates
GuruFocus News • 3:31pm
May 11, 2025
Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Release
GuruFocus News • 4:56pm
May 07, 2025
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
Business Wire • 7:00am
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News
GuruFocus News • 6:49am
Apr 30, 2025
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
Business Wire • 4:00pm
Apr 15, 2025
Arrowhead Pharmaceuticals Announces CFO Transition | ARWR stock news
GuruFocus News • 4:01pm
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
Business Wire • 4:00pm
Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Retires | ARWR Stock News
GuruFocus News • 3:16pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news